Our mission is to conquer cancer.

Rakuten Medical is a privately funded, global clinical-stage biotechnology company with offices in the U.S., Japan, Taiwan, Germany and the Netherlands. We aim to become a leader in precision-targeted medicines through our proprietary cancer treatment platform Illuminox™. Our lead product, ASP-1929, the first investigational product based on Illuminox, has achieved Fast Track designation from the FDA and Sakigake Designation from the Japanese Ministry of Health, Labour and Welfare. ASP-1929 is currently the subject of a global, Phase 3 clinical trial for recurrent head and neck squamous cell carcinoma. Additional Phase 2 studies for ASP-1929 are also underway to evaluate safety in patients with other types of cancer.

For more information, visit www.rakuten-med.com.